Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.

Modest DP, Brodowicz T, Stintzing S, Jung A, Neumann J, Laubender RP, Ocvirk J, Kurteva G, Papai Z, Knittelfelder R, Kirchner T, Heinemann V, Zielinski CC.

Oncology. 2012;83(5):241-7. Epub 2012 Aug 29.

PMID:
22948721
2.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

García-Foncillas J, Díaz-Rubio E.

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Review.

PMID:
20709651
3.

KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL.

Cancer. 2013 Feb 15;119(4):714-21. doi: 10.1002/cncr.27804. Epub 2012 Sep 12. Review.

4.

Role of cetuximab in first-line treatment of metastatic colorectal cancer.

Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E.

World J Gastroenterol. 2014 Apr 21;20(15):4208-19. doi: 10.3748/wjg.v20.i15.4208. Review.

5.

[The development of the first line treatment of metastatic colorectal cancer (mCRC)].

Landherr L, Nagykálnai T.

Magy Onkol. 2009 Sep;53(3):237-46. doi: 10.1556/MOnkol.53.2009.3.1. Review. Hungarian.

6.

Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.

Peeters M, Price T.

Cancer Treat Rev. 2012 Aug;38(5):397-406. doi: 10.1016/j.ctrv.2011.08.002. Epub 2011 Sep 6. Review.

PMID:
21899955
7.

Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.

Moosmann N, Heinemann V.

Clin Colorectal Cancer. 2008 Mar;7(2):110-7. doi: 10.3816/CCC.2008.n.015. Review.

PMID:
18501070
8.

Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.

Cheng AL, Li J, Vaid AK, Ma BB, Teh C, Ahn JB, Bello M, Charoentum C, Chen LT, de Lima Lopes G Jr, Ho GF, Kong HL, Lam KO, Liu TS, Park YS, Sriuranpong V, Sudoyo AW, Wang JY, Zhang J, Zhang SZ, Ciardiello F, Köhne CH, Shaw M, Kim TW.

Clin Colorectal Cancer. 2014 Sep;13(3):145-55. doi: 10.1016/j.clcc.2014.06.004. Epub 2014 Jun 26.

PMID:
25209093
9.

KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?

Hebbar M, Fournier P, Romano O.

Eur J Cancer Care (Engl). 2010 Mar;19(2):167-71. doi: 10.1111/j.1365-2354.2009.01134.x. Epub 2009 Aug 20. Review.

PMID:
19702696
10.

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.

Westwood M, van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, Noake C, Ross J, Severens J, Kleijnen J.

Health Technol Assess. 2014 Oct;18(62):1-132. doi: 10.3310/hta18620. Review.

11.

Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.

Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM.

World J Gastroenterol. 2014 Apr 21;20(15):4263-75. doi: 10.3748/wjg.v20.i15.4263. Review.

12.

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

Li W, Shi Q, Wang W, Liu J, Ren J, Li Q, Hou F.

Colorectal Dis. 2014 Nov;16(11):O370-8. doi: 10.1111/codi.12749. Review.

PMID:
25155261
13.

Cetuximab in the treatment of patients with colorectal cancer.

Garrett CR, Eng C.

Expert Opin Biol Ther. 2011 Jul;11(7):937-49. doi: 10.1517/14712598.2011.582464. Epub 2011 May 11. Review.

PMID:
21557708
14.

Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.

Lyseng-Williamson KA.

Mol Diagn Ther. 2012 Oct;16(5):317-22. doi: 10.1007/s40291-012-0007-2. Review.

PMID:
23055389
15.

Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.

Lee JJ, Chu E.

Clin Colorectal Cancer. 2014 Sep;13(3):135-44. doi: 10.1016/j.clcc.2014.02.001. Epub 2014 Feb 27. Review.

16.

Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature.

Barni S, Ghilardi M, Borgonovo K, Cabiddu M, Zaniboni A, Petrelli F.

Rev Recent Clin Trials. 2013 Jun;8(2):101-9. Review.

PMID:
23859115
17.

Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.

Chen J, Ye Y, Sun H, Shi G.

Cancer Chemother Pharmacol. 2013 Jan;71(1):265-72. doi: 10.1007/s00280-012-2005-9. Epub 2012 Oct 23. Review.

PMID:
23090619
18.

Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis.

Yang YF, Wang GY, He JL, Wu FP, Zhang YN.

Medicine (Baltimore). 2017 Mar;96(12):e6335. doi: 10.1097/MD.0000000000006335. Review.

19.

Cetuximab in metastatic colorectal cancer.

Broadbridge VT, Karapetis CS, Price TJ.

Expert Rev Anticancer Ther. 2012 May;12(5):555-65. doi: 10.1586/era.12.25. Review.

PMID:
22594891
20.

Common side effects and interactions of colorectal cancer therapeutic agents.

Holt K.

J Pract Nurs. 2011 Spring;61(1):7-20. Review. No abstract available.

PMID:
21751717

Supplemental Content

Support Center